Consider buying Hims & Hers Health (HIMS), as it is viewed as the clear winner in direct-to-consumer healthcare and is currently trading at a very cheap valuation. The market is incorrectly valuing HIMS as only a GLP-1 company, overlooking its highly diversified and profitable businesses in erectile dysfunction, hair loss, and anxiety. Its superior marketing and new generic offerings, like a user-friendly liraglutide injector pen, provide a strong competitive edge. In contrast, Talkspace (TALK) is a high-risk stock to avoid due to the long-term threat of its therapy business being disrupted by free AI alternatives. TALK also faces significant risk from its dependence on a small number of large contracts, making its revenue potentially unstable.

Hims & Hers Health, Inc. (HIMS)

• The speaker is very bullish on HIMS, calling it the "clear winner" among the direct-to-consumer healthcare stocks discussed.
• The stock is considered very cheap, trading at a valuation metric of 0.1 (EV/GP/RG), the same as its competitor LifeMD.
• Recent stock price declines are attributed to "fear-mongering headlines" that incorrectly portray HIMS as a GLP-1 only story.
• The business is highly diversified beyond weight loss, with significant revenue from:
  • Erectile Dysfunction (ED)
  • Hair loss
  • Anxiety medication
• The weight loss business itself is also diversified and not solely reliant on compounded drugs. Key offerings include:
  • Metformin-based weight loss pills, which are 100% generic and owned by HIMS.
  • A new generic liraglutide (a generic GLP-1) that comes with a user-friendly injector pen, which is seen as a major competitive advantage over vial-and-needle injections.
  • The company offers a compelling price structure compared to name brands:
    • Ozempic: $1,800/month
    • HIMS Generic Liraglutide: $399/month
    • HIMS Compounded GLP-1: $165/month
• The speaker praises HIMS for its superior marketing, which makes customers "feel cool" and removes the stigma from treatment, leading to better patient adherence and a high net promoter score.
• The business model is viewed as stable due to its large, diversified customer base of over 2 million monthly subscribers, which protects it from the risk of losing a few large contracts.

Takeaways

• The speaker believes the market is misjudging HIMS by focusing too narrowly on the risks associated with compounded GLP-1 drugs.
• The company's diversified product lines (anxiety, ED, hair loss) and multiple weight loss options (generic pills, generic injectables) provide a significant buffer against regulatory or competitive pressures in any single area.
• HIMS is positioned as a disruptor, using technology and a mass-market strategy to lower healthcare costs and increase access, which is a powerful long-term theme.
• Given its high growth rate and cheap valuation, the speaker considers HIMS the most attractive investment in the sector.

LifeMD, Inc. (LFMD)

• LifeMD is a direct competitor to HIMS and is noted to be trading at the exact same cheap valuation metric of 0.1.
• The stock recently had a "really bad day," likely falling in sympathy with the negative sentiment around the direct-to-consumer health sector and HIMS.
• The speaker acknowledges LifeMD has had an "outstanding run" over the past few months.

Takeaways

• While LFMD is as cheap as HIMS on the speaker's valuation metric, the speaker implies a strong preference for HIMS based on its perceived level of growth and success.
• Investors looking for a cheap entry into the direct-to-consumer health space could consider LFMD, but the speaker's analysis suggests HIMS is the superior choice.

Talkspace, Inc. (TALK)

• The speaker is bearish on Talkspace and has exited their position (a call option expired worthless).
• The primary risk identified is the rapid advancement of AI, specifically free AI therapist tools like the one available in Grok. The speaker believes many discussion-based professions, including therapy, will see their value "collapse to the cost of electricity."
• The business model is considered high-risk because it relies on large contracts with government entities (e.g., New York City Department of Mental Hygiene) and school districts.
• This customer concentration creates "binary event" risk, where the loss of a single contract due to a decision by a few people could severely impact revenue.

Takeaways

• The long-term viability of Talkspace's human-led therapy model is in question due to the emergence of free and effective AI alternatives.
• The stock is considered a risky investment due to its dependence on a small number of large contracts, making its revenue streams potentially unstable. The speaker prefers the diversified, subscription-based model of HIMS.

GoodRx Holdings, Inc. (GDRX)

• The speaker has a neutral to slightly bearish view on GoodRx.
• The stock is described as cheap, trading at 2 times forward sales, but suffers from very low growth (4% predicted for the next 12 months).
• The core business is a well-known coupon app for prescription drugs, but it is seen as being late to enter lucrative, high-growth verticals like ED treatment.
• The company's marketing and branding are described as "very 20th century" and "medical," lacking the modern, consumer-friendly appeal of competitors like HIMS.
• While GoodRx is now offering ED medication for $21 a month (cheaper than HIMS), the speaker is skeptical of their ability to market it effectively against more brand-savvy competitors.

Takeaways

• GoodRx is a value play with a well-known brand, but its low-growth profile makes it less attractive than its peers.
• The company's struggle to innovate and adapt its marketing for modern consumers may hinder its ability to compete in new, high-margin categories.

Teladoc Health, Inc. (TDOC)

• Teladoc is characterized as a "value stock" or a "savings account stock"—stable but with very low growth.
• The stock is cheap on a price-to-revenue basis, trading at 0.67 times its revenue.
• Growth is expected to be extremely slow at 1%, with the potential for it to be flat or even decline.
• Its business model is primarily B2B, selling telehealth services to employers and health plans, rather than directly to consumers.
• The acquisition of BetterHelp is viewed as a mistake for which the company overpaid.
• However, the recent acquisition of Catapult Health (a provider of on-site mobile clinics for employers) is seen as a very positive and "wonderful fit."

Takeaways

• TDOC may appeal to a value-focused investor who prioritizes a low valuation over growth potential.
• The speaker is personally not interested in the stock due to its slow growth, which contrasts sharply with a company like HIMS.
• The company has a solid, established business with positive customer reviews and is making some smart strategic acquisitions (Catapult Health), but it is not a high-growth story.